Last reviewed · How we verify
Sunitinib and Erlotinib
At a glance
| Generic name | Sunitinib and Erlotinib |
|---|---|
| Also known as | Sutent, Tarceva |
| Sponsor | Clinical Research Management, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- The Drug Rediscovery Protocol (DRUP Trial) (PHASE2)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (PHASE2)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Bevacizumab in Multiple Phase I Combinations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sunitinib and Erlotinib CI brief — competitive landscape report
- Sunitinib and Erlotinib updates RSS · CI watch RSS
- Clinical Research Management, Inc. portfolio CI